Next Article in Journal
Preserving Genome Integrity during the Early Embryonic DNA Replication Cycles
Next Article in Special Issue
Single Fragment or Bulk Soil DNA Metabarcoding: Which is Better for Characterizing Biological Taxa Found in Surface Soils for Sample Separation?
Previous Article in Journal
Protein Changes in Response to Lead Stress of Lead-Tolerant and Lead-Sensitive Industrial Hemp Using SWATH Technology
Previous Article in Special Issue
Full-Length Multi-Barcoding: DNA Barcoding from Single Ingredient to Complex Mixtures
Open AccessArticle

Detecting Schisandrae Chinensis Fructus and Its Chinese Patent Medicines with a Nucleotide Signature

1
Key Lab of Chinese Medicine Resources Conservation, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China
2
The Pangenomics Group, School of Science, RMIT University, Melbourne 3083, Australia
*
Author to whom correspondence should be addressed.
Genes 2019, 10(5), 397; https://doi.org/10.3390/genes10050397
Received: 11 April 2019 / Revised: 16 May 2019 / Accepted: 17 May 2019 / Published: 22 May 2019
(This article belongs to the Special Issue DNA Barcoding and Metabarcoding of Complex Matrices)
Schisandrae Chinensis Fructus (Wuweizi) is often adulterated with Schisandrae Sphenantherae Fructus (Nanwuweizi) in the herbal market. This adulteration is a threat to clinical treatment and safety. In this study, we aimed to develop a nucleotide signature for the identification of Wuweizi and its Chinese patent medicines based on the mini-DNA barcoding technique. We collected 49 samples to obtain internal transcribed spacer 2 (ITS2) sequences and developed a 26-bp nucleotide signature (5′-CGCTTTGCGACGCTCCCCTCCCTCCC-3′) on the basis of a single nucleotide polymorphism (SNP) site within the ITS2 region that is unique to Wuweizi. Then, using the nucleotide signature, we investigated 27 batches of commercial crude drug samples labeled as Wuweizi and eight batches of Chinese patent medicines containing Wuweizi. Results showed that eight commercial crude drug samples were adulterants and one of the Chinese patent medicines contained adulterants. The nucleotide signature can serve as an effective tool for identifying Wuweizi and its Chinese patent medicines and can thus be used to ensure clinical drug safety. View Full-Text
Keywords: Wuweizi; Chinese patent medicines; identification; nucleotide signature Wuweizi; Chinese patent medicines; identification; nucleotide signature
Show Figures

Figure 1

MDPI and ACS Style

Jiang, W.; Ren, L.; Guo, M.; Mantri, N.; Zhao, S.; Pang, X. Detecting Schisandrae Chinensis Fructus and Its Chinese Patent Medicines with a Nucleotide Signature. Genes 2019, 10, 397.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop